Penpulimab

Anlotinib

Degan LuPhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 45/ 100
Competitive Position: 89/ 100

Competitive context

9 Active assets in the Anlotinib cohort.

Asset / Sponsor	Phase	Rating
Catequentinib Nanfang Hospital, Southern Medical University	Phase 3	BB
Benmelstobart Nanfang Hospital, Southern Medical University	Phase 3	BB
Irinotecan First People's Hospital of Hangzhou	Phase 2	CCC
Docetaxel First People's Hospital of Hangzhou	Phase 2	CCC
Carboplatin Wenjun Cheng	Phase 2	CCC

View all 19 →

Same molecule, other indications

Penpulimab is also rated in:

hepatocellular carcinomaDormant

BB

Indicative ·

70 / 100

non-small cell lung carcinomaDormant

BB

Indicative ·

68 / 100

lung cancerDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.